ChemicalBook > CAS DataBase List > Parecoxib

Parecoxib

Product Name
Parecoxib
CAS No.
1709956-95-5
Chemical Name
Parecoxib
Synonyms
Parecoxib;ValdecoxibImpurity39;Parecoxib Impurity 33;Valdecoxib Impurity N;3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl Chloride;Benzenesulfonyl chloride, 3-(5-methyl-3-phenyl-4-isoxazolyl)-
CBNumber
CB6951641
Molecular Formula
C16H12ClNO3S
Formula Weight
333.79
MOL File
1709956-95-5.mol
More
Less

Parecoxib Property

Melting point:
165-167°C
Boiling point:
459.4±45.0 °C(Predicted)
Density 
1.340±0.06 g/cm3(Predicted)
storage temp. 
Refrigerator
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
-3.44±0.50(Predicted)
form 
Solid
color 
White to Off-White
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

TRC
Product number
M305725
Product name
3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonylChloride
Packaging
1mg
Price
$165
Updated
2021/12/16
Usbiological
Product number
462055
Product name
Parecoxib
Packaging
10mg
Price
$305
Updated
2021/12/16
More
Less

Parecoxib Chemical Properties,Usage,Production

Uses

Anti-inflammatory; analgesic (cyclooxygenase COX-2 inhibitor).

Uses

3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl Chloride is an Impurity of Parecoxib Sodium (P193275), an anti-inflammatory, analgesic.

Clinical Use

Parecoxib is a pro-drug of valdecoxib administered IM or IV for perioperative analgesic and anti-inflammatory use. As a pro-drug, it undergoes rapid in vivo hydrolysis to valdecoxib.Parecoxib at greater than 20 mg has analgesic activity superior to that of placebo and similar to that of parenteral 30 or 60 mg of ketorolac in patients with postoperative dental pain. A significant adverse effect is drug hypersensitivity. Parecoxib is currently marketed worldwide but has not been approved for use in the United States.

Synthesis

The acylation of 4-(5-methyl- 3-phenylisoxazol-4-yl)benzenesulfonamide (valdecoxib), with propionic anhydride in a solution of triethanolamine (TEA) and 4-dimethylaminophenol (DMAP) in tetrahydrofuran gives N-propionamide, which is treated with NaOH in ethanol to give the sodium salt of parecoxib .

Drug interactions

Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
Antibacterials: possible increased risk of convulsions with quinolones.
Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban.
Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
Antidiabetics: possibly enhanced effect of sulphonylureas.
Antiepileptics: possibly enhanced effect of phenytoin.
Antifungals: if used with fluconazole reduce the dose of parecoxib.
Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
Ciclosporin: potential for increased risk of nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate, (possible increased risk of toxicity); increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity; possible antagonism of diuretic effect; increased risk of hyperkalaemia with potassium-sparing diuretics.
Lithium: reduced excretion of lithium (risk of toxicity).
Pentoxifylline: possibly increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.

Metabolism

Parecoxib is rapidly and almost completely converted to valdecoxib and propionic acid.
Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulphonamide moiety. Excretion is mainly via the urine with about 70% of a dose appearing as inactive metabolites. No unchanged parecoxib is found in the urine with only trace amounts in the faeces.

Parecoxib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Parecoxib Suppliers

BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Country
United States
ProdList
14055
Advantage
65
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-4000505016 13380397412
Fax
0755 28094224
Email
3001272453@qq.com
Country
China
ProdList
5050
Advantage
50
Shanghai Kewel Chemical Co., Ltd.
Tel
021-64609169 18901607656
Fax
021-64609160
Email
greensnown@163.com
Country
China
ProdList
9906
Advantage
50
Hubei Yangxin Medical Technology Co., Ltd.
Tel
15374522761
Fax
QQ:2853117752
Email
3003392093@qq.com
Country
China
ProdList
8369
Advantage
55
Shenzhen Polymeri Biochemical Technology Co., Ltd.
Tel
+86-400-002-6226 +86-13028896684;
Email
sales@rrkchem.com
Country
China
ProdList
56902
Advantage
58
Guangzhou Dreampharm Biotechnology Co., Ltd.
Tel
020-36607679 17825480238
Fax
QQ 3008233717
Email
3008233717@qq.com
Country
China
ProdList
9919
Advantage
12
Standardpharm Co. Ltd.
Tel
86-714-3992388
Email
overseasales1@yongstandards.com
Country
United States
ProdList
14332
Advantage
58
Jinan blalong chemical co. LTD
Tel
2710913286@.com
Email
1513643261@qq.com
Country
China
ProdList
14246
Advantage
58
Meng Cheng Technology (Shanghai) Co., LTD
Tel
400-820-6829
Email
sales@mitachieve.com
Country
China
ProdList
8860
Advantage
58
SHENZHEN PHYSTANDARD BIO-TECH CO.,LTD
Tel
0755-0755-0755-83725350 13380397412
Fax
0755-28094224
Email
3001280422@qq.com
Country
China
ProdList
10003
Advantage
58

1709956-95-5, ParecoxibRelated Search:


  • Parecoxib
  • Valdecoxib Impurity N
  • Parecoxib Impurity 33
  • 3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl Chloride
  • Benzenesulfonyl chloride, 3-(5-methyl-3-phenyl-4-isoxazolyl)-
  • ValdecoxibImpurity39
  • 1709956-95-5
  • 10.98470-84-7